[{"symbol": "AXSM", "publishedDate": "2026-01-16 12:15:13", "title": "Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia", "image": "https://images.financialmodelingprep.com/news/axsome-therapeutics-begins-phase-iii-study-on-axs14-for-20260116.jpg", "site": "zacks.com", "text": "AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.", "url": "https://www.zacks.com/stock/news/2818973/axsome-therapeutics-begins-phase-iii-study-on-axs-14-for-fibromyalgia?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2818973"}, {"symbol": "AXSM", "publishedDate": "2026-01-15 10:51:26", "title": "Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term", "image": "https://images.financialmodelingprep.com/news/why-axsome-therapeutics-axsm-is-a-top-momentum-stock-20260115.jpg", "site": "zacks.com", "text": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "url": "https://www.zacks.com/stock/news/2818116/why-axsome-therapeutics-axsm-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2818116"}, {"symbol": "AXSM", "publishedDate": "2026-01-12 16:20:00", "title": "MoneyShow's Best Investment Ideas For 2026: Part 2", "image": "https://images.financialmodelingprep.com/news/moneyshows-best-investment-ideas-for-2026-part-2-20260112.jpg", "site": "seekingalpha.com", "text": "MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.", "url": "https://seekingalpha.com/article/4858926-moneyshow-best-investment-ideas-for-2026-part-2"}, {"symbol": "AXSM", "publishedDate": "2026-01-12 07:00:00", "title": "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue", "image": "https://images.financialmodelingprep.com/news/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-20260112.jpg", "site": "globenewswire.com", "text": "Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively", "url": "https://www.globenewswire.com/news-release/2026/01/12/3216700/33090/en/Axsome-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenue.html"}, {"symbol": "AXSM", "publishedDate": "2026-01-09 12:40:48", "title": "HALO or AXSM: Which Is the Better Value Stock Right Now?", "image": "https://images.financialmodelingprep.com/news/halo-or-axsm-which-is-the-better-value-stock-20260109.jpg", "site": "zacks.com", "text": "Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers value investors a better bang for their buck right now?", "url": "https://www.zacks.com/stock/news/2815166/halo-or-axsm-which-is-the-better-value-stock-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_3-2815166"}]